Evidence map›Paper›PMID 29430618›Full record

ArticleMolecular neurobiology2018

Design, Synthesis, and In Vitro Evaluation of a Novel Probucol Derivative: Protective Activity in Neuronal Cells Through GPx Upregulation.

Ruth Liliám Quispe, Rômulo Faria Santos Canto, Michael Lorenz Jaramillo, Flavio Augusto Rocha Barbosa, Antônio Luiz Braga, Andreza Fabro de Bem, Marcelo Farina

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular neurobiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Ruth Liliám QuispePrograma de Pós-Graduação em Neurociências, Universidade Federal de Santa Catarina, Campus Universitário, Florianópolis, SC, Brazil. ruth.liliam@gmail.com.
Rômulo Faria Santos CantoDepartamento de Farmacociências, Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre, RS, Brazil.
Michael Lorenz JaramilloDepartamento de Biologia Celular, Embriologia e Genética, Universidade Federal de Santa Catarina, Campus Universitário, Florianópolis, SC, Brazil.
Flavio Augusto Rocha BarbosaDepartamento de Química, Centro de Ciências Biológicas, Universidade Federal de Santa Catarina, Florianópolis, SC, 88040-900, Brazil.
Antônio Luiz BragaDepartamento de Química, Centro de Ciências Biológicas, Universidade Federal de Santa Catarina, Florianópolis, SC, 88040-900, Brazil.
Andreza Fabro de BemDepartamento de Bioquímica, Centro de Ciências Biológicas, Universidade Federal de Santa Catarina, Campus Universitário, Trindade, Bloco C, CEP, Florianópolis, Santa Catarina, Brazil.
Marcelo FarinaPrograma de Pós-Graduação em Neurociências, Universidade Federal de Santa Catarina, Campus Universitário, Florianópolis, SC, Brazil. marcelo.farina@ufsc.br.ORCID http://orcid.org/0000-0001-8255-8515
Universidade Federal de Santa Catarina · BRUniversidade Federal de Ciências da Saúde de Porto Alegre · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent studies have shown that probucol (PB), a hipocholesterolemic agent with antioxidant and anti-inflammatory properties, presents neuroprotective properties. On the other hand, adverse effects have limited PB's clinical application. Thus, the search for PB derivatives with no or less adverse effects has been a topic of research. In this study, we present a novel organoselenium PB derivative (RC513) and investigate its potential protective activity in an in vitro experimental model of oxidative toxicity induced by tert-butyl hydroperoxide (tBuOOH) in HT22 neuronal cells, as well as exploit potential protective mechanisms. tBuOOH exposure caused a significant decrease in the cell viability, which was preceded by (i) increased reactive species generation and (ii) decreased mitochondrial maximum oxygen consumption rate. RC513 pretreatment (48 h) significantly prevented the tBuOOH-induced decrease of cell viability, RS generation, and mitochondrial dysfunction. Of note, RC513 significantly increased glutathione peroxidase (GPx) activity and mRNA expression of GPx1, a key enzyme involved in peroxide detoxification. The use of mercaptosuccinic acid, an inhibitor of GPx, significantly decreased the protective activity of RC513 against tBuOOH-induced cytotoxicity in HT22 cells, highlighting the importance of GPx upregulation in the observed protection. In summary, the results showed a significant protective activity of a novel PB derivative against tBuOOH-induced oxidative stress and mitochondrial dysfunction, which was related to the upregulation of GPx. Our results point to RC513 as a promising neuroprotective molecule, even though studies concerning potential beneficial effects and safety aspects of RC513 under in vivo conditions are well warranted.

Indexed as

Drug DesignUp-RegulationAnimalsCell LineCell SurvivalGlutathione PeroxidaseGlutathione Peroxidase GPX1MiceMitochondriaNeuronsNeuroprotective AgentsOxidative StressOxygen ConsumptionProbucolRNA, MessengerSulfhydryl Compounds2-thiomalic acidGlutathione PeroxidaseGlutathione Peroxidase GPX1Gpx1 protein, mouseNeuroprotective AgentsProbucolRNA, MessengerSulfhydryl Compoundstert-ButylhydroperoxideThiomalatesGlutathione peroxidaseHT22 cellsMitochondrial dysfunctionProbucol derivativetBuOOH

Identifiers

PMID29430618
OpenAlexW2790413384

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.